DOCSLIB.ORG

Detection of Varicella-Zoster Virus Dna in Ocular Samples from Patients with Uveitis but No Cutaneous Eruption

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Detection of Varicella-Zoster Virus Dna in Ocular Samples from Patients with Uveitis but No Cutaneous Eruption DETECTION OF VARICELLA-ZOSTER VIRUS DNA IN OCULAR SAMPLES FROM PATIENTS WITH UVEITIS BUT NO CUTANEOUS ERUPTION P. STAVROUI, S. M. MITCHELL2, J. D. FOX", M. W. HOPE-ROSSi and P. I. MURRAY I SUMMARY with intraocular inflammation can be a diagnostic Herpes zoster ophthalmicus is a well-recognised cause of dilemma when there is no history of rash or evidence of intraocular inflammation, which may become recurrent skin scarring.IA.9 In the past, the availability of only small or chronic after the acute phase has elapsed. Although it volumes of ocular fluid and the high prevalence of serum commonly presents with the typical rash, cases of ocular antibodies to herpes viruses in the general popUlation has zoster with no cutaneous eruption have been well docu­ meant that making a specific diagnosis in such circum­ mented. We present two patients with unilateral anterior stances has been difficult. Recently, molecular techniques uveitis complicated by cataract, in whom molecular tech­ based on the polymerase chain reaction (PCR) have been niques based on the polymerase chain reaction detected applied successfully to a variety of ocular samples to iden­ 0- varicella-zoster virus DNA in intraocular material tify viruses in cases of intraocular inflammation.1 16 The obtained during cataract surgery. Neither patient gave a PCR has proven advantages as a diagnostic aid in view of history of cutaneous eruption. its specificity for amplification of specific genomic Herpes zoster ophthalmicus (HZO) is a common disease sequences from an infectious agent, requiring only minute caused by the reactivation of latent infection by the vari­ specimens and giving results within several hours. cella-zoster virus (VZV).1-4 An important complication is We present two patients with unilateral uveitis of anterior uveitis, which develops in 43-53% of patients.4-6 unknown aetiology and no history of cutaneous eruption. Its onset may be delayed for months after the disappear­ In both patients VZV DNA was isolated from intraocular ance of the rashlA.5 and can vary in severity from mild to samples obtained during cataract surgery, after ampli­ severe.1.4 Keratic precipitates, anterior and posterior syn­ fication by the PCR. echiae are common,2.7 and iris atrophy, although usually a PATIENTS AND METHODS late manifestation, may occasionally be present during the acute stage.1 .7 This is characterised by sectoral loss of iris Case I pigment epithelium and migration of pigment into the A 62-year-old healthy, immunocompetent, Caucasian overlying stroma and is thought to be secondary to an male initially presented to the Accident & Emergency occlusive vasculitis.H8 Posterior subcapsular cataract Department of the Birmingham and Midland Eye Hospital may develop as a result of chronic uveitis or prolonged use in September 1990, complaining of a red, painful left eye of topical steroids.1A Secondary glaucoma, seen in associated with blurred vision of 9 days' duration. His past 15-43% of patients with anterior uveitis due to HZO,s is ocular history was unremarkable. He was found to have a thought to be due to a combination of several mechanisms left anterior uveitis with 'mutton fat' keratic precipitates, including trabeculitis and plugging of the trabecular dense flare and cells, posterior synechiae, an intraocular meshwork with debris and cells, posterior synechiae caus­ pressure of 22 mmHg and a visual acuity reduced to 6/18. ing pupillary block and anterior synechiae causing angle The other eye was normal. He improved on topical ster­ closure.IA oids and was discharged after 2 months. While the clinical diagnosis of HZO is relatively easy He re-presented 6 days later with a relapse of the uvei­ when the typical cutaneous eruption is present, patients tis. At that visit, sectoral iris atrophy was noted. Routine From: 'Birmingham & Midland Eye Hospital, Birmingham. UK; uveitis investigations were negative except for an elevated 'Department of Medical Microbiology. Division of Virology. University plasma viscosity of 1.88 cP (normal range: 1.50-1.72 cP). College London Medical School. London, UK. The anterior uveitis became chronic in nature and a pos­ Correspondence to: Mr P. L Murray. PhD. FRCS, FRCOphth. Academic Unit of Ophthalmology. Birmingham and Midland Ey e terior subcapsular cataract developed. Hospital, Church Street. Birmingham B3 2NS. UK. Fax: 021-233 9213. In December 1992 he underwent a left extracapsular Eye (1994) 8, 684-687 © 1994 Royal College of Ophthalmologists VARICELLA-ZOSTER DNA IN UVEITIS 685 cataract extraction which was complicated by vitreous out, followed by a 7 minute extension at 72 °c using an loss, although a posterior chamber intraocular lens (IOL) automated thermal cycler. The reaction conditions for the was implanted. During the operation, aqueous humour, second round of PCR were as for the first except that the lens nucleus and vitreous humour were obtained. mix contained 100 ng of each ' inner' primer pair and I III His chronic uveitis persisted afterhis cataract extraction of the first-round product. For detection of the second­ and while his immediate post-operative acuity was 6/18, it round product, 25 cycles were sufficient. The first- and deteriorated to 6/36 in June 1993 due to cystoid macular second-round products were analysed by electrophoresis oedema (CMO). Although the CMO resolved after a peri­ using a 2% agarose gel and were visualised at 302 nm ocular injection of depot steroid, his visual acuity remains after staining with ethidium bromide. The extracted at 6/18 due to posterior lens capsular thickening. In view material from lens nucleus was treated in a similar way of the sector iris atrophy, there was a clinical suspicion of and lO-fold dilutions were added to the PCR reaction. VZV being the cause of this patient's chronic unilateral Aqueous samples were also obtained at cataract extrac­ uveitis. tion from 20 control patients with senile cataract and 20 patients with Fuchs' heterochromic cyclitis who acted as a Case 2 disease control group.211 A 55-year-old healthy, immunocompetent, Caucasian male has been attending the Birmingham and Midland RESULTS Eye Hospital since 1976 with a recurrent left anterior uvei­ In the aqueous samples no VZV, HSV-J or CMV DNA tis and secondary glaucoma. His other eye has always sequences could be detected in either case. In the vitreous been quiet. Routine uveitis investigations have been samples VZV DNA but not HSV-I or CMV DNA was normal except for a positive Mantoux test in 1976. As a detected in case I; no herpesviral DNA sequences were result of his recurrent inflammation he developed a pos­ found in case 2. In the lens nucleus VZV DNA but not terior subcapsular cataract. HSV-J or CMV DNA was detected in case 2; no herpes­ In January 1993 he underwent an uneventful extra­ viral DNA sequences were found in case 1. capsular cataract extraction and a heparin surface-modi­ No herpesviral DNA sequences were found in aqueous fied posterior chamber IOL was implanted. During the samples from either control group. operation, aqueous humour and lens nucleus were obtained. DISCUSSION Post-operatively, his visual acuity improved to 6/6 and Although viruses have been implicated as causative agents he still continues on topical steroid and beta-blocker. As in various forms of uveitis,1,lllIS,ln,21-29 the clinical diag- this patient's hypertensive anterior uveitis had always nosis can occasionally be difficult, particularly in atypical been unilateral over 17 years, there was a clinical sus­ cases. Confirmation of a viral aetiology using laboratory picion of herpes simplex virus-I (HSV-I) being the aeti­ techniques usually is unsatisfactory as demonstration of ological agent. antiviral antibodies in the serum does not confirm end­ organ disease. Increased concentration of specific anti­ Methodfor the Detection of Herpesviral DNA in bodies in aqueous humour and vitreous is also an indirect Ocular Samples sign of viral infection. Culturing herpes viruses from All ocular samples were taken under sterile conditions and intraocular fluids is difficult, requires relatively large then stored at -50°C. Prior to analysis, the aqueous and amounts of sample, and may take a considerable time until vitreous humour samples were boiled for 10 minutes then the result is known. Recent work by a variety of authors rapidly cooled on ice. The lens nucleus samples were dis­ has shown the value of applying molecular techniques solved in buffer containing sodium dodecyl sulphate and based on the PCR to the detection of herpes viruses in III-In proteinase K, boiled for 10 minutes, then incubated over­ ocular samples. Inherent to these techniques is their night at 37°C. rapidity, sensitivity and specificity when compared with The nested PCR method used for the detection of viral previous laboratory-based methods. DNA sequences from VZV gene 29, HSV-l gD and cyto­ The molecular technique used detected fragments of megalovirus (CMV) gB in ocular fluids has been reported VZV DNA and as such does not indicate actively repli­ previousl/S.16 and was applied to the ocular samples from cating virus. Treatment of the samples does not differen­ the patients described here. The method utilises oligonu­ tiate between cell-associated viral DNA and 'free' virus. cleotide primers adapted from those described by Maha­ Nevertheless, fragments of unencapsulated viral DNA are IX lingham et al.,17 Aurelius et 01. and Darlington et 01.19 unlikely to persist without being degraded, so our findings The first-round reaction mix contained 10 mM Tris-HCI almost certainly reflect the presence of VZV, latent or pH 8.3, 50 mM KCI, 1.5 mM MgCI , I unit of Taq poly­ otherwise. Also, as herpesviral DNA was not present in 2 merase (Perkin Elmer Cetus, ILS Ltd, London), 200 11M the controls, it is highly probable that VZV was the of each dNTP, 100 ng of each 'outer' primer and J III of causative agent of the intraocular inflammation.
Load more

Recommended publications
  • Human Herpesvirus 6 in Cerebrospinal Fluid of Patients Infected with HIV
    J Neurol Neurosurg Psychiatry 1999;67:789–792 789 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.67.6.789 on 1 December 1999. Downloaded from SHORT REPORT Human herpesvirus 6 in cerebrospinal fluid of patients infected with HIV: frequency and clinical significance Simona Bossolasco, Roberta Marenzi, Helena Dahl, Luca Vago, Maria Rosa Terreni, Francesco Broccolo, Adriano Lazzarin, Annika Linde, Paola Cinque Abstract convulsions or other neurological symptoms The objective was to evaluate the fre- complicating exanthema subitum.2–4 HHV-6 quency of human herpesvirus 6 (HHV-6) encephalitis or milder neurological symptoms DNA detection in the CSF of patients have been described in both immunocompet- infected with HIV and its relation to brain ent adults and transplanted patients,5–7 and the disease and systemic HHV-6 infection. virus might also play an aetiological part in Nested polymerase chain reaction multiple sclerosis.8 HHV-6 has also been found (PCR) was used to analyse CSF samples in the brain or CSF of adults and children with from 365 consecutive HIV infected pa- AIDS, but its role in neurological disease is still tients with neurological symptoms. When unclear.9–12 available, plasma and brain tissues from To study the possible relation between patients whose CSF was HHV-6 positive HHV-6 and brain disease in patients infected were also studied. with HIV, the presence of HHV-6-DNA in the HHV-6 was found in the CSF of eight of CSF was assessed in a large group of patients copyright. Division of Infectious the 365 patients (2.2%): two had type A with neurological disease and was correlated Diseases, San RaVaele and four type B; the HHV-6 variant could with clinical and neuropathology patterns.
    [Show full text]
  • Herpesviral Latency—Common Themes
    pathogens Review Herpesviral Latency—Common Themes Magdalena Weidner-Glunde * , Ewa Kruminis-Kaszkiel and Mamata Savanagouder Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima Str. 10, 10-748 Olsztyn, Poland; [email protected] (E.K.-K.); [email protected] (M.S.) * Correspondence: [email protected] Received: 22 January 2020; Accepted: 14 February 2020; Published: 15 February 2020 Abstract: Latency establishment is the hallmark feature of herpesviruses, a group of viruses, of which nine are known to infect humans. They have co-evolved alongside their hosts, and mastered manipulation of cellular pathways and tweaking various processes to their advantage. As a result, they are very well adapted to persistence. The members of the three subfamilies belonging to the family Herpesviridae differ with regard to cell tropism, target cells for the latent reservoir, and characteristics of the infection. The mechanisms governing the latent state also seem quite different. Our knowledge about latency is most complete for the gammaherpesviruses due to previously missing adequate latency models for the alpha and beta-herpesviruses. Nevertheless, with advances in cell biology and the availability of appropriate cell-culture and animal models, the common features of the latency in the different subfamilies began to emerge. Three criteria have been set forth to define latency and differentiate it from persistent or abortive infection: 1) persistence of the viral genome, 2) limited viral gene expression with no viral particle production, and 3) the ability to reactivate to a lytic cycle. This review discusses these criteria for each of the subfamilies and highlights the common strategies adopted by herpesviruses to establish latency.
    [Show full text]
  • Current in Vivo Models of Varicella-Zoster Virus Neurotropism
    viruses Review Current In Vivo Models of Varicella-Zoster Virus Neurotropism Ravi Mahalingam 1,* , Anne Gershon 2 , Michael Gershon 3, Jeffrey I. Cohen 4, Ann Arvin 5, Leigh Zerboni 5, Hua Zhu 6 , Wayne Gray 7, Ilhem Messaoudi 8 and Vicki Traina-Dorge 9 1 Department of Neurology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA 2 Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; [email protected] 3 Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; [email protected] 4 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; [email protected] 5 Pediatric Infectious Disease, Stanford University, Stanford, CA 94305, USA; [email protected] (A.A.); [email protected] (L.Z.) 6 Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ 07102, USA; [email protected] 7 Biology Department, University of Mississippi, Oxford, MS 38677, USA; [email protected] 8 Departments of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA 92697, USA; [email protected] 9 Division of Microbiology, Tulane University, Tulane National Primate Research Center, Covington, LA 70433, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-303-724-4324 Received: 1 February 2019; Accepted: 28 May 2019; Published: 31 May 2019 Abstract: Varicella-zoster virus (VZV), an exclusively human herpesvirus, causes chickenpox and establishes a latent infection in ganglia, reactivating decades later to produce zoster and associated neurological complications.
    [Show full text]
  • Management of Varicella Zoster Virus (Vzv) Infections
    MANAGEMENT OF VARICELLA ZOSTER VIRUS (VZV) INFECTIONS Federal Bureau of Prisons Clinical Guidance DECEMBER 2016 Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient- specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp Federal Bureau of Prisons Management of VZV Infections Clinical Guidance December 2016 WHAT’S NEW IN THIS DOCUMENT? What is new in the December 2016 version of this document? • Duplication of information is minimized. • Varicella IgM testing is not recommended for either suspected varicella cases or contacts, because of low sensitivity and specificity (see Appendix 1, Varicella Testing). • Procedures for contact investigation have been simplified and clarified (see Appendix 3, Varicella Contact Investigation Checklist). • VariZIG for post-exposure prophylaxis is now commercially available. What was new in the December 2011 version of this document? • A digital Varicella Timeline Calculator (for determining the exposure and infectious periods of an index case and the incubation period of exposed contacts) was added to the BOP website (http://www.bop.gov/resources/health_care_mngmt.jsp). • Treatment of post-herpetic neuralgia associated with herpes zoster was clarified (see Treatment of Herpes Zoster/Shingles in Section 6, Treatment). • It was emphasized that inmates with herpes zoster (shingles) should be housed in a single cell if the secretions from the lesions cannot be easily contained (see Housing Inmates with Varicella or Herpes Zoster in Section 7, Control Measures).
    [Show full text]
  • Varicella-Zoster Virus ORF9 Is an Antagonist of the DNA Sensor Cgas ABSTRACT
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.11.943415; this version posted February 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Varicella-Zoster Virus ORF9 Is an Antagonist of the DNA Sensor 2 cGAS 3 4 Jonny Hertzog1, Rachel E. Rigby1, Sonja Roll1, Chiara Cursi1, Lise Chauveau1, Tamara 5 Davenne1, and Jan Rehwinkel1,* 6 7 1MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, 8 Radcliffe Department of Medicine, University of Oxford, Oxford, UK 9 10 *correspondence: [email protected] 11 12 13 ABSTRACT 14 15 Varicella-Zoster virus (VZV) causes chickenpox and shingles. Although infection is 16 associated with severe morbidity in some individuals, the molecular mechanisms that 17 determine innate immune responses remain poorly defined. We found that the 18 cGAS/STING DNA sensing pathway was critically required for type I interferon (IFN) 19 induction in response to VZV infection. Viral gene overexpression screening identified 20 the essential VZV tegument protein ORF9 as a novel antagonist of DNA sensing via 21 cGAS. Ectopically as well as virally expressed ORF9 bound to endogenous cGAS. 22 Confocal microscopy revealed co-localisation of cGAS and ORF9, which blocked the 23 type I IFN response to transfected DNA. ORF9 and cGAS also interacted directly in a 24 cell-free system. Our data further suggest that ORF9 inhibited the production of 25 cGAMP by cGAS.
    [Show full text]
  • Herpes Simplex and Varicella–Zoster Virus Infections
    MJA PracticeMJ EssentialsA Practice Essentials InfectiousInfectious Diseases Diseases 10: Herpes simplex and varicella–zoster virus infections Dominic E Dwyer and Anthony L Cunningham The availability of effective antiviral therapy makes early diagnosis vital HERPES SIMPLEX VIRUS types 1 and 2 and varicella–zoster Abstract virus are unique members of the Herpesviridae family, as they Thecan Medical infect Journalboth skin of Australia and nerves ISSN: 0025-729Xand develop 2 September latent ■ Any new patient with suspected genital herpes should infection2002 177within 5 267-273 the dorsal root and trigeminal ganglia. have diagnostic testing with virus identification. Infection©The withMedical these Journal viruses of Australia is common 2002 www.mja.com.au and causes a wide ■ Type-specific serological tests that distinguish between MJA Practice Essentials — Infectious Diseases range of clinical syndromes. Although these viruses infect antibodies for type 1 and type 2 herpes simplex virus healthy children and adults, disease is more severe and (HSV) may be useful to determine previous exposure but extensive in the immunocompromised. cannot be used to diagnose recurrences of genital herpes. ■ Initial episodes of genital herpes usually require antiviral Herpes simplex virus therapy, while recurrences may be treated with continuous antiviral suppression (if frequent) or episodic Pathogenesis and epidemiology therapy; patient counselling and education (including how to recognise lesions) are essential. Herpes simplex virus (HSV; Box 1) infects
    [Show full text]
  • The Role of Viral Glycoproteins and Tegument Proteins in Herpes
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2014 The Role of Viral Glycoproteins and Tegument Proteins in Herpes Simplex Virus Type 1 Cytoplasmic Virion Envelopment Dmitry Vladimirovich Chouljenko Louisiana State University and Agricultural and Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Veterinary Pathology and Pathobiology Commons Recommended Citation Chouljenko, Dmitry Vladimirovich, "The Role of Viral Glycoproteins and Tegument Proteins in Herpes Simplex Virus Type 1 Cytoplasmic Virion Envelopment" (2014). LSU Doctoral Dissertations. 4076. https://digitalcommons.lsu.edu/gradschool_dissertations/4076 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. THE ROLE OF VIRAL GLYCOPROTEINS AND TEGUMENT PROTEINS IN HERPES SIMPLEX VIRUS TYPE 1 CYTOPLASMIC VIRION ENVELOPMENT A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Pathobiological Sciences by Dmitry V. Chouljenko B.Sc., Louisiana State University, 2006 August 2014 ACKNOWLEDGMENTS First and foremost, I would like to thank my parents for their unwavering support and for helping to cultivate in me from an early age a curiosity about the natural world that would directly lead to my interest in science. I would like to express my gratitude to all of the current and former members of the Kousoulas laboratory who provided valuable advice and insights during my tenure here, as well as the members of GeneLab for their assistance in DNA sequencing.
    [Show full text]
  • Comprehensive Analysis of Varicella-Zoster Virus Proteins Using a New Monoclonal Antibody Collection
    Comprehensive Analysis of Varicella-Zoster Virus Proteins Using a New Monoclonal Antibody Collection Tihana Lenac Roviš,a Susanne M. Bailer,b,c Venkata R. Pothineni,b Werner J. D. Ouwendijk,d Hrvoje Šimic´,a Marina Babic´,e Karmela Miklic´,a Suzana Malic´,a Marieke C. Verweij,f Armin Baiker,b,g Orland Gonzalez,h Albrecht von Brunn,b Ralf Zimmer,h Klaus Früh,f Georges M. G. M. Verjans,d Stipan Jonjic´,a,e Jürgen Haasb,i Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatiaa; Max von Pettenkofer Institut, Ludwig-Maximilians Universität München, München, Germanyb; University of Stuttgart, Biological Interfacial Engineering, Stuttgart, Germanyc; Department of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlandsd; Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatiae; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USAf; Bavarian Health and Food Safety Authority, Oberschleissheim, Germanyg; Institute for Bioinformatics, Ludwig-Maximilians Universität München, München, Germanyh; Division of Pathway Medicine, University of Edinburgh, Edinburgh, United Kingdomi Varicella-zoster virus (VZV) is the etiological agent of chickenpox and shingles. Due to the virus’s restricted host and cell type tropism and the lack of tools for VZV proteomics, it is one of the least-characterized human herpesviruses. We generated 251 monoclonal antibodies (MAbs) against 59 of the 71 (83%) currently known unique VZV proteins to characterize VZV protein expression in vitro and in situ. Using this new set of MAbs, 44 viral proteins were detected by Western blotting (WB) and indi- rect immunofluorescence (IF); 13 were detected by WB only, and 2 were detected by IF only.
    [Show full text]
  • Structure–Function Analysis of Varicella-Zoster Virus Glycoprotein H Identifies Domain-Specific Roles for Fusion and Skin Trop
    Structure–function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism Susan E. Vlecka,b,1,2, Stefan L. Olivera,b,1, Jennifer J. Bradyb, Helen M. Blaub, Jaya Rajamania,b, Marvin H. Sommera,b, and Ann M. Arvina,b Departments of aPediatrics and bMicrobiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305 Edited by Bernard Roizman, University of Chicago, Chicago, IL, and approved September 30, 2011 (received for review July 17, 2011) Enveloped viruses require membrane fusion for cell entry and re- into four domains rather than the three proposed for HSV gH plication. For herpesviruses, this event is governed by the multi- (12–14). The overall structures are comparable, although EBV protein core complex of conserved glycoproteins (g)B and gH/gL. gH/gL form a rod-like structure due to disparate interdomain The recent crystal structures of gH/gL from herpes simplex virus 2, packing angles. The PRV gH structure lacks the N terminus and pseudorabies virus, and Epstein–Barr virus revealed distinct do- gL but shows similar architecture in the regions classified as DII mains that, surprisingly, do not resemble known viral fusogens. and DIII in HSV gH (12, 13). Varicella-zoster virus (VZV) causes chicken pox and shingles. VZV is Previous studies of gH/gL using expression vectors and com- an α-herpesvirus closely related to herpes simplex virus 2, enabling plementation assays demonstrate that HSV-1 and EBV gH re- prediction of the VZV gH structure by homology modeling. We gions now mapped to DI have functions in fusion and integrin fi fi binding (6, 15–17).
    [Show full text]
  • Advances and Perspectives in the Management of Varicella-Zoster Virus Infections
    molecules Review Advances and Perspectives in the Management of Varicella-Zoster Virus Infections Graciela Andrei * and Robert Snoeck Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; [email protected] * Correspondence: [email protected]; Tel.: +32-16-32-19-51 Abstract: Varicella-zoster virus (VZV), a common and ubiquitous human-restricted pathogen, causes a primary infection (varicella or chickenpox) followed by establishment of latency in sensory ganglia. The virus can reactivate, causing herpes zoster (HZ, shingles) and leading to significant morbidity but rarely mortality, although in immunocompromised hosts, VZV can cause severe disseminated and occasionally fatal disease. We discuss VZV diseases and the decrease in their incidence due to the introduction of live-attenuated vaccines to prevent varicella or HZ. We also focus on acyclovir, valacyclovir, and famciclovir (FDA approved drugs to treat VZV infections), brivudine (used in some European countries) and amenamevir (a helicase-primase inhibitor, approved in Japan) that augur the beginning of a new era of anti-VZV therapy. Valnivudine hydrochloride (FV-100) and valomaciclovir stearate (in advanced stage of development) and several new molecules potentially good as anti-VZV candidates described during the last year are examined. We reflect on the role of antiviral agents in the treatment of VZV-associated diseases, as a large percentage of the at-risk population is not immunized, and on the limitations of currently FDA-approved anti-VZV drugs. Their low efficacy in controlling HZ pain and post-herpetic neuralgia development, and the need of Citation: Andrei, G.; Snoeck, R. multiple dosing regimens requiring daily dose adaptation for patients with renal failure urges the Advances and Perspectives in the development of novel anti-VZV drugs.
    [Show full text]
  • Chapter 22: Varicella; Epidemiology and Prevention of Vaccine
    Varicella Adriana Lopez, MHS; Theresa Harrington, MD, MPH&TM; and Mona Marin, MD Varicella is an acute infectious disease caused by varicella- zoster virus (VZV). Primary varicella infection (chickenpox) Varicella was not reliably distinguished from smallpox until the end of ● Acute infectious disease caused the 19th century. In 1875, Rudolf Steiner demonstrated that by varicella-zoster virus (VZV) chickenpox was caused by an infectious agent by inoculating ● Distinguished from smallpox at volunteers with the vesicular fluid from a patient with acute the end of the 19th century varicella. In 1954, Thomas Weller used cell culture to isolate VZV from vesicular fluid of patients with varicella or zoster. A ● Live, attenuated varicella vaccine developed in 1970s live, attenuated varicella vaccine was developed in Japan in the 1970s. The vaccine virus was developed from virus isolated ● Varicella and MMRV vaccines by Michiaki Takahashi from vesicular fluid from an otherwise licensed for use in the U.S. in healthy child with varicella disease. Varicella vaccine was 1995 and 2005, respectively licensed for general use in Japan and Korea in 1988, and in the United States in 1995 for persons age 12 months or older. In 2005, a combination measles, mumps, rubella, and varicella (MMRV) vaccine was licensed in the United States for persons Varicella-Zoster Virus (VZV) age 12 months through 12 years. ● Herpesvirus (DNA) ● Primary infection results in varicella (chickenpox) Varicella-Zoster Virus ● Reactivation of latent infection VZV is a DNA virus and is a member of the herpesvirus results in herpes zoster group. Like other herpesviruses, VZV persists in the body as a (shingles) latent infection after the primary (first) infection; VZV persists ● Short survival in environment in sensory nerve ganglia.
    [Show full text]
  • (KSHV/HHV-8) to SCID-Hu Thy/Liv Mice by D
    Experimental Transmission of Kaposi’s Sarcoma–associated Herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv Mice By D. Dittmer,‡§ C. Stoddart,*i R. Renne,‡§ V. Linquist-Stepps,*i M.E. Moreno,*i C. Bare,*i J.M. McCune,*i and D. Ganem‡§ From the *Departments of Microbiology and Medicine, ‡Department of Microbiology and Immunology and Department of Medicine, and §Howard Hughes Medical Institute, University of California, San Francisco, California 94143; and iGladstone Institute of Virology and Immunology, San Francisco, California 94110 Summary Kaposi’s sarcoma–associated herpesvirus (KSHV/HHV-8) is a novel human lymphotropic her- pesvirus linked to several human neoplasms. To date, no animal model for infection by this vi- rus has been described. We have examined the susceptibility of C.B-17 scid/scid mice implanted with human fetal thymus and liver grafts (SCID-hu Thy/Liv mice) to KSHV infection. KSHV virions were inoculated directly into the implants, and viral DNA and mRNA production was Downloaded from assayed using real-time quantitative polymerase chain reaction. This revealed a biphasic infec- tion, with an early phase of lytic replication accompanied and followed by sustained latency. Ultraviolet irradiation of the inoculum abolished all DNA- and mRNA-derived signals, and infection was inhibited by ganciclovir. Viral gene expression was most abundant in CD191 B lymphocytes, suggesting that this model faithfully mimics the natural tropism of this virus. www.jem.org Short-term coinfection with HIV-1 did not alter the course of KSHV replication, nor did KSHV alter levels of HIV-1 p24 during the acute phase of the infection.
    [Show full text]